The updated, revised edition of this acclaimed book offers authoritative guidance on trends in diagnosis and mortality, new PSA isoforms for diagnosis, PSA screening, chemoprevention, biopsy techniques, sural nerve grafting and hereditary prostate cancer.

Eric A. Klein, MD Cleveland Clinic, Glickman Urological and Kidney Institute, Cleveland, OH, USA J. Stephen Jones, MD Cleveland Clinic, Glickman Urological and Kidney Institute, Cleveland, OH, USA

Prostate Cancer: Past, Present, and Future Patrick Walsh Epidemiology and Risk Factors Otis Brawley (ACS) Twenty years and counting: is PSA still useful in 2009? Screening for Prostate Cancer: Proven or Not? Proven: Bill Catalona (Northwestern) Not: Fritz Schroder (Erasmus University) Beyond PSA: EPCA2, PCA3 and ETS Fusion Genes Leonard Marks (LA) Hereditary Prostate Cancer and Genetic Risk Kathleen Cooney (Univ Mich) Lessons from the Prostate Cancer Prevention Trial Ian Thompson (UTHSC San Antonio) Nutrition and Obesity Stephen Freedland (Duke) Molecular Progression of Prostate Cancer IGF axis: M. Pollack Inflammation: W. Nelson Stem Cells: R. Reiter Infection: E. Klein Androgens and Estrogens: Don Tindall CAG Repeats: Doug Figg (NCI) Epigenetics: Mark Gonzalgo (JHU) Chemoprevention: Fact or Fiction? Current Issues in Pathologic Evaluation Cristina Magi-Galluzzi (CCF) Optimum Prostate Biopsy: Technique and Strategies J. Stephen Jones (CCF) The Utility of Nomograms in Routine Clinical Practice Andrew Stephenson (CCF) Active Surveillance Comes of Age Laurie Klotz (Toronto)/ Peter Carroll (UCSF) Who Dies from Prostate Cancer? Andrew Stephenson (CCF) Focal Therapy David Crawford (Univ Colorado) Radical Prostatectomy: Does the Approach Matter? Eric Klein Contemporary External Beam Radiotherapy: Image Guidance and Hypofractionation Pat Kupelian (MDACC Orlando) or Howard Sandler (Univ of Michigan) Contemporary Brachytherapy Radiation, Surgery or Brachytherapy for Low and Intermediate Risk Disease? E. Klein, Jay Ciezki, Arul Mahadevan and Pat Kupelian (CCF and MDACC) What is the Optimum Management for Locally Advanced Disease? Patient Reported Outcomes and Satisfaction with Surgery, Brachytherapy and Radiation: results of the PROSQA Study Marty Sanda (Beth Israel, Boston) Current Management of Post-prostatectomy Impotence and Incontinence John Mulhall (MSKCC, impotence) and Courtney Moore (CCF, incontinence) Management of Biochemical Failure Matt Simmons (CCF) Management of Newly Diagnosed Metastatic Disease Thomas Hutson (US Oncology) Management of Hormone Refractory Disease Rob Dreicer (CCF) Pitfalls of Hormone Therapy Tim Gilligan (CCF)/Matt Smith (Harvard) Bone Targeted Therapy Oliver Sartor (Oschner Clnic) PSMA for Imaging and Therapy Skip Heston (CCF)